The Myeloma Beacon Staff's Archive

The Myeloma Beacon Staff has written 725 article(s) .

[ by | Dec 10, 2014 3:12 pm | 3 Comments ]
ASH 2014 Multiple Myeloma Update - Day Two: Education Session And Midday Oral Session

This past Sunday was the second day of the American Society of Hema­tology’s (ASH) annual meeting, which was held in San Francisco.

As on the first day of the meeting, myeloma-related pre­sen­ta­tions once again took place during several sessions throughout the day.

A myeloma-related education session held the first day of the conference was repeated once again on Sunday morning.

While the education session was being held, a separate “scientific sym­po­sium” with two oral pre­sen­ta­tions took place in parallel.  The …

Tags: , , , , , , , , , , , , , ,
Read the full story »
[ by | Dec 8, 2014 7:02 am | 5 Comments ]
ASH 2014 Multiple Myeloma Update – Day One: Poster Session

Saturday was the official first day of the 2014 American Society of Hema­tology (ASH) annual meeting. The day featured a wide range of interesting pre­sen­ta­tions about multiple myeloma.

Oral presentations about new treatments under development were given mid-day and were summarized in a Beacon ASH Daily Update published yesterday morning.

During Saturday evening, a poster session took place where important new research findings were summarized in posters displayed throughout two separate large conference halls.

The studies covered a variety of …

Tags: , , , , , , , , , , ,
Read the full story »
[ by | Dec 5, 2014 7:41 am | 4 Comments ]
ASH 2014 Preview: New Multiple Myeloma Treatments On The Horizon

The 2014 annual meeting of the American Society of Hematology (ASH) starts tomorrow, December 5, in San Francisco, and will continue until next Tuesday.

The ASH annual meeting is one of several large medical conferences where myeloma-related research findings are presented each year.  However, from a multiple myeloma perspective, the ASH meeting is generally the most important of the meetings.

At this year’s meeting, for example, some 500 myeloma-presentations are scheduled to take place.  The presentations will summarize current research …

Tags: , , , , , , , , , , , , , , ,
Read the full story »
[ by | Nov 25, 2014 3:02 pm | One Comment ]
FDA Postpones Decision On Panobinostat Approval Application

The U.S. Food and Drug Administration (FDA) has postponed for up to three months its decision on pano­bino­stat’s new drug application.

The FDA action was announced earlier this morning in a press release issued by Novartis (NYSE:NVS), the Swiss pharmaceutical company developing pano­bino­stat as a potential new multiple myeloma therapy.

A decision on pano­bino­stat’s application for FDA approval had been expected by the end of this week. The decision was widely anticipated to be a negative one, …

Tags: , , ,
Read the full story »
[ by | Nov 6, 2014 5:18 pm | One Comment ]
Panobinostat Fails In Bid For FDA Advisory Committee Support

Panobinostat had an important appointment this morning with a group of on­col­o­gists.

The appointment did not go so well.

The Oncologic Drugs Advisory Committee (ODAC) of the U.S. Food and Drug Administration (FDA) conducted a four-hour review of panobinostat (Farydak) earlier today.

At the end of the meeting, members of the committee were asked to vote whether they felt the benefits of panobinostat as a potential treatment for relapsed myeloma outweighed its risks.

Five committee members voted "no." …

Tags: , , ,
Read the full story »